Medica leads to NHS partnership for IMSTA Member PMD Solutions

Ltor: Michael Collins, Irish Ambassador to Germany, Dr Tom Kelly – Head of Industrial, Lifesciences and Consumer Division at Enterprise Ireland, Sean Kinsella, PMD Solutions CTO, Anne Dorney, PMD Solutions, CFO, Pat Breen, Minister for Trade, Employment, Business, EU Digital Single Market and Data Protection and Myles Murray, PMD Solution CEO. 


Provider of respiratory monitoring technology PMD Solutions has been selected to join the NHS Innovation Accelerator Programme.

The NHS Innovation Programme is a partnership between England’s 15 Academic Health Science Networks (AHSNs) and is focused on working with healthcare innovators.

The announcement from the world’s largest healthcare conference Medica, where PMD Solutions was showcasing its RespiraSense product, a device which can continuously monitor patients’ respiratory rates. The device can help detect patient deterioration up to 12 hours in advance of an adverse patient event, allowing healthcare professionals to intervene faster.

PMD Solutions was invited by Enterprise Ireland to be part of the Irish pavilion where they represented alongside some of the world’s leading medtec organisations.

The NHS will rapidly adopt the company’s RespiraSense product to help improve the standard of care throughout the UK. The device is currently being piloted in Portsmouth, Bradford and London hospitals as part of the Innovation Programme.

RespiraSense is currently awaiting FDA clearance but PMD Solutions expect it to be available for sale within the US sometime next year.

Minister for Trade, Employment, and Business, Pat Breen TD said: “I am delighted but not surprised with PMD Solutions’ recent successes. I had the pleasure of visiting them at this year’s Medica event and was extremely impressed by their high levels of innovation and entrepreneurship. It is wonderful to see an Irish company at the forefront of medical technology advances. They serve as a great example to all Irish companies with ambitions to trade internationally.”

Sheila O’Loughlin, senior market adviser, Enterprise Ireland said: “PMD Solutions has achieved significant traction in the UK market, further strengthened by its recent acceptance on the prestigious NHS Innovation Accelerator Programme. We will continue to support them as they expand in to European and global markets.”

Speaking about the company’s recent successes, Myles Murray, CEO, PMD Solutions said: “We are most grateful to Enterprise Ireland for giving us this fantastic opportunity to showcase RespiraSense to the global healthcare industry. We have created an innovation that is set to change the face of in hospital monitoring at a global scale, improve patient outcomes and generate substantial cost savings for healthcare providers.”

Murray continued: “We are a young company with big ambition. The recent NHS announcement, coupled with Medica has allowed us to engage with global leaders and positioned PMD as an international clinical differentiator in the patient monitoring market.”

IMSTA Members attend updated Code of Ethics Business Breakfast

With the implementation deadline for the updated MedTech Code of Ethical Business Practice less than 1 month away, IMSTA hosted a Breakfast Briefing to inform members of the two major changes which they should be aware of.     Melanie Robertson (Siemens Healthineers), Chairperson of the Code of Ethics Group, kindly updated members of the following changes:

  1. Stopping Direct Sponsorship to Healthcare Practitioners (HCPs).  As of January 1, 2018, it will no longer be allowed for companies to provide direct financial support to individual HCPs to attend either local or international Third Party Organised Events (e.g. congresses). Instead, support can be offered through Educational Grants provided to Healthcare Organisations (HCOs) or Professional Conference Organisers (PCOs).   The message here was very clear that Education Grants can only be provided to Healthcare Organisations or PCOs, and member companies cannot themselves select the person who should be the recipient of this Grant.  They can however suggest a specific area of expertise who should benefit from the Grant.  
  1. Public disclosure by Member Companies of their Educational Grants: as of January 1, 2018, companies providing Educational Grants to HCOs will be publicly disclosing the aggregated amount of all Educational Grants, provided to HCOs over the year of 2017, on the Transparent MedTech system.   The disclosure deadline is 30 June 2018, for publication in August.  

IMSTA Members can avail of templates etc which are available on the Med Tech Europe website by following the link here.  Melanie also included some useful information which should assist the smooth adaption of the changes in her slide presentation available on request from  This included information on how to navigate the MedTech Europe Conference Vetting System (CVS).    This Conference Vetting System is an independently managed system that reviews the compliance of third-party educational conferences with the MTE Code of Ethical Business Practice, based on clear and objective criteria.  For more information on this please see Med Tech Europe link above. 

If any member would like more information or have any comments to make on the changes to the Code of Ethical Business Practice, please email .



WINNER - BEATS MEDICAL Health Exercises for Parkinsons Patients.

(ltor) John Carew and Ciara Clancy (Beats Medical) , and Tom Kelly (Enterprise Ireland).

WINNER - ABBOTT DIABETES CARE for their FreeStyle Libre Flash Glucose Monitoring System.

(ltor) Colm McNulty and Barbara Scott (Abbott Diabetes Care), Tom Kelly (Enterprise Ireland) and Mark Coffey (Vice Chair IMSTA)

WINNER - OXYGEN CARE Technical support

(ltor) Brian Kearney (BEAI), Andie Healy, Maurice Moran and David Moran (Oxygen Care).


(ltor) Barry Heaton and Nigel Clancy (Smith & Nephew) with Mark Coffey (Vice Chair IMSTA).

WINNER - BD PosiFlush™ Pre-Filled Saline Syringe training and staff efficiency programme.

(ltor) Ms. Mary Jacob (RCSI), Greg Quinn (BD) and Mark Coffey (Vice Chair IMSTA).

WINNER - CAREFOLK Integrated care platform.

(ltor) David Cass (Pathfinder), Owen O'Dohety (Carefolk) and Mark Coffey (Vice Chair, IMSTA).

WINNER - HSE Primary Care Project Development and introduction of the Risk-Sentience Auxiliary Framework.

(ltor) Mark Coffey (Vice Chair IMSTA), Jerry Selvaseelan (HSE) and Dr. Mairead O'Driscoll (HRB).

WINNER - VICLARITY Healthcare Solution

(ltor) Dr. Colman Casey (HIHI), Ogie Sheehy (VICLARITY) and Mark Coffey (Vice Chair IMSTA).

WINNER - CAREFOLK Integrated Care Platform.

(ltor) Alan Wallace (Mangan O'Beirne), Owen O'Doherty (Carefolk) and Mark Coffey (Vice Chair IMSTA).


MED TECH Europe have shared the attached HAI updated brochure.  It is important to note that this is a revamp and update of an already existing information sheet, with new data, new calls for action (in line with our position paper) and a clear link made between AMR and HAIs. The brochure showcases the different medical technologies that can prevent and control HAIs throughout the patient pathway.


MES SEMINAR – 21st April – Presentations now available

“This is a must see event for IMSTA members who want to compete for MES contracts in the future.”


Dr. Joris van den Hurk, Care IQ, The Netherlands – “Introduction to Managed Equipment Services (MES); An International Perspective”

Caroline Finlay, MTS Health UK – “Managed Services – The Value Proposition”

Nancy West, Head of Enterprise Services and Solutions, Siemens Healthcare, UK – “Evolution of MES”

David French, Independent Healthcare Advisor – “Driving Value through Authentic Partnerships”

Patricia Egan, Beacon Hospital Ireland – “Managing an MES – Reflections on an Exciting First Year”

Caroline Hobson and Paul Smith, CMS Cameron McKenna, UK – “Legal Framework, Contractual Issues, Procurement, SME Involvement”

Gráinne Crowley, Project Officer, Sligo University Hospital, Saolta University Health Care Group – “Managed Services – the User Perspective” Setting it up – the ‘‘Team Approach’’

Dr. Peter Ellis “Managed Equipment Service – Royal Victoria Hospital”


MES SEMINAR – Friday 21st April 2017

Registration – 10.00 to 10.30 a.m.

Venue – The Emmet Theatre, ARTS Building, TRINITY COLLEGE, Dublin 2.

No parking at venue, parking nearby in Setanta Centre.

Enter via Nassau Street Entrance.

For late registrations please contact Joanne on

Register HERE

See Agenda here :MES Seminar Agenda



The Future Lies in Value-Based Healthcare: Why we need to encourage our customers to base procurement decisions on more than the purchasing price

Justin Carty, CEO of IMSTA spoke with Irish Times journalist Sylvia Thompson

The cheapest product rarely gives customers the best value, according to Justin Carty, the CEO of the Irish Medical and Surgical Trade Association.  Representing products ranging from bandages to CAT scans, Carty has to navigate a careful route when promoting the medical device industry to public and private hospital purchasers keen to get the best value for money with limited budgets.

But, as luck would have it, Carty’s agenda fits completely with the new EU public procurement directive.  This 2014 EU directive presents a holistic analysis of value based health care which evaluates the entire life cycle, safety and effectiveness of products and not just the purchasing price.  It also encourages the industry to define best price-quality ratio and to collaborate more closely with purchasers at the pre-tendering phase.

A recent report from the Boston Consulting Group, commissioned by Med Tech Europe (of which IMTSA is a member) presents a clear picture on how things need to change.  Currently, most health care providers purchase medical products on the basis of the up-front purchase price, which, the consultants argue cloud the true cost of care.

The report includes insightful examples of what happens when broader criteria are used to purchase equipment.  Take for instance, the Karolinska University Hospital in Sweden whose foutreen year tender for imaging services which included MRI, ultrasound and CT scanners; by tendering for imaging services rather than equipment, the contract included maintenance of technical standards, upgrades and replacement during the fourteen year period.  Similarly, when the Stockholm County Council (which runs most of the city’s hospitals) sought tenders for wound care products, it asked suppliers to include calculations for the number of dressing changes, staff and transportation costs for changing these dressings.  The winning bid was from the highest priced products which showed a lower cost of care over time.

The Boston Consulting Group report argues that smarter procurement such as these examples embraces a value-based framework that is aligned with the new EU directive.   To include all the hidden costs of the equipment in terms of its durability and suitability to patient’s needs, the group suggests a calculation based on patient outcomes divided by the costs of achieving these outcomes.

Carty hopes this more holistic approach to procurement will be embraced by healthcare providers in Ireland.  “This new procurement process focuses more on how to achieve better patient outcomes,” he says.  Carty also suggests it would encourage clinicians to work more closely with the medical technology industry rather than leaving procurement decisions to those with their eyes firmly placed on the purchase price alone.

A natural extension of this approach would, according to Carty, be for healthcare providers to seek solutions to ongoing problems through industry competitions.  This already happens in some countries such as the UK where the Small Business Innovation Research (SBIR) mechanism is used.   There, NHS England’s SBRI Healthcare has worked with companies to come up with new solutions to problems in diverse areas such as diabetic foot ulcers, child and adolescent mental health and brain injury.  The key element of effective SBIR programmes is that clinicians and front-line staff are the ones to identify the unmet need.

In his role as CEO of IMSTA, Carty proposed the SBIR model to a cross-departmental committee at Government level in 2015.

“We proposed that one to two per cent of the HSE non-pay procurement budget of €500 million could be ring-fenced to find solutions to identified healthcare problems,” he explains.    The proposal was repeated in the IMSTA submission to the Oireachtas Committee on the Future of Healthcare in August 2016.  As yet, the model hasn’t been embraced by the Health Services Executive.

Now, in 2017, Carty is keen to move the agenda forwards.  To that end, Value-Based Healthcare Strategies is the theme of the IMSTA Annual Conference in the Crown Plaza Hotel, Santry on March 22.  Confirmed speakers include Dr Tom Kelley from ICHOM, the International Consortium for Health Outcomes Measurement, Bill Maher, the CEO of the Bons Secours Hospital Group and Frank Sullivan, Adjunct Professor in Medicine and Director of Prostate Cancer Institute, NUIG.  Throughout the conference, delegates will hear about the role of healthcare innovation in improving patient and clinical outcomes. Proposals for a new economic evaluation framework for medtech will also be discussed. 

Ultimately, Carty is keen to spread the message about the role of medical technology companies in helping people live longer, healthier and more productive lives.   “These life changing innovations also bring savings across the health care system by replacing more expensive procedures, reducing hospital stays and allowing people to return to work and home more quickly,” says Carty.

However, he adds a note of caution. “In order to understand the value and benefits of medical technology and ensure continued leadership of this industry, we must have the right public policies to support investment, innovation and patient access.”

Article for IMSTA Newsletter, Spring 2017

IMSTA supports MedTech Week 19-23 June 2017

#MedTechWeek 2017 activities out now! 

From 19 – 23 June   IMSTA , Medtech companies and Trade Associations from across Europe joined together to communicate the value that medical devices and in vitro diagnostics deliver to people, health systems and the wider economy.   IMSTA participated in several events during this week and the lightlights can be enjoyed below.

IMSTA are newest partners to donation scheme – The EQUALS Initiative.  The EQUALS Initiative was established between The Royal College of Physicians of Ireland and the HSE, and is based on developing strong links with hospitals while providing support according to the needs identified for equipment and training – 50 in-patient beds, 20 labour and delivery ward beds and 10 ultrasound machines being donated.  Details of the latest EQUALS Initiative were confirmed today as part of 2017 #medtechweek which is being hosted by IMSTA.

Speaking today, Justin Carty of IMSTA said: We are delighted to be on board with this positive and virtuous initiative as it continues to go from strength to strength. Many of our members in the medical technology sector would have supplied the equipment being donated and they will be heartened to know that it can still have a significant impact after being taken out of service in Ireland.   IMSTA’s access to medical equipment coupled with our bioengineering expertise can support the work of EQUALS in donating equipment and providing training in equipment maintenance in Zambia and other less developed countries.  This will enable hospitals in these countries to provide essential safe and high-quality health care which will address medical needs and save lives.”

“IMSTA recognizes the vital role of medical technology in contributing to the development of healthcare services and to address the unmet equipping and training needs in less developed countries.  Alike with our partners on EQUALS, we are deeply committed to the common goal of contributing to the improvement of global health.

Launching the new collaboration with IMSTA, Professor Frank Murray, President of the Royal College of Physicians of Ireland, said: “The healthcare and training needs are substantial in Zambia. We see opportunities to improve outcomes there in partnership with the authorities in Zambia. Healthcare equipment from Ireland has a huge potential to deliver benefits in Zambia. We look forward to collaborating with IMSTA to optimize opportunities to benefit Zambian patients. RCPI and HSE have developed a significant collaboration around training and equipment in this area, and the involvement of IMSTA has the possibility of bringing this to a higher level. It fulfills part of our mission statement to improve patient outcomes.”

Justin and Prof. Murray were interviewed afterwards on Newstalk’s Global Village programme and you can access the podcast here

To celebrate 2017 MedTech Week in Ireland, the Irish Medical & Surgical Trade Association (IMSTA) joined forces with global brand Vanilla Blush to showcase the company’s fashion and medical range of stoma underwear for patients.

Justin Carty, CEO of the Irish Medical & Surgical Trade Association (IMSTA) said: “Vanilla Blush’s specially designed underwear support and conceal stomas,  which greatly improves patient experiences allowing people with stomas to live full normal lives. IMSTA believes in supporting products which do just that.  Patient experience matters and is proven to effect health outcomes. Vanilla Blush products are available in the NHS but they are not reimbursed in Ireland by the HSE’s Primary Care Reimbursement System (PCRS). One has to ask why? It is our hope that this will change and these products will be reimbursed to Irish patients in time.”

Nicola Dames, the Dublin-born Vanilla Blush CEO, added: “We all have specialised individual needs. And we all have individual medical technological help. I so happen to need additional support with my Stoma. Other people need other help. This is what I call a normality of needs.”

Justin Carty, IMSTA, participated in a roundtable discussion, hosted by Medtronic, to mark MedTech Week 2017 on Tuesday June 20th at Buswells Hotel.   

DUBLIN – June 20, 2017  82% of Irish men and women have said they want easier access to innovative surgical treatments to treat incontinence and support a better quality of life, according to new research by Medtronic plc (NYSE: MDT).

The research was carried out by iReach, on behalf of Medtronic to mark MedTech Week 2017, with 1001 people (48% male, 52% female) across Ireland sampled from the 26th May to 1st June 2017 using an online survey and a consumer panel.

The data, presented at a MedTech Week event, has also found that:

  • Just 35% would be comfortable reporting their incontinence problems to a nurse, 32% to a consultant, 14% to a friend and 11% to a physiotherapist. Just 39% of adults surveyed would be comfortable talking about their incontinence to a family member and 14% to a friend.
  • 55% of respondents are likely to accept non-invasive surgical treatment in order to resolve issues with incontinence, with 50% of respondents also willing to consider physiotherapy;
  • Compared to all cohorts, middle-aged adults are most likely to favour non-invasive surgical treatments, with 61% of males selecting this treatment option as a means to resolve issues with incontinence;

To celebrate MedTech Week 2017, Medtronic also hosted a roundtable discussion to consider the research findings with patient groups, clinicians and representatives of the medical technology sector.  Participants emphasised that incontinence remains an under-treated condition as Irish patients remain uncomfortable in seeking treatment, as the research has revealed, and supported a call for the Irish healthcare system to harness the potential of innovative incontinence treatments to enhance patient outcomes. There was also agreement in calling for the optimisation of care pathways to ensure the most comprehensive treatments for pelvic floor disorders are available to patients in Ireland.

In a subsequent parliamentary exhibition, which was attended by TDs, Senators and patients, innovative bladder and bowel control therapies enabled by medical technology were put on display. Attendees were also given a first-hand account of how the use of such therapies can bring about significant improvements in the quality of life of incontinence sufferers. 

Speaking at the event, Dr. Mary Pat Fitzgerald, Consultant Gynaecologist at Bon Secours Hospital Galway, said: “Bladder control problems can significantly impair the quality of our lives, and as our discussions today have shown many patients are too embarrassed or uncomfortable to talk about the problem with a medical professional. It is critically important that we bring this condition out in the open so another generation does not suffer in silence.”

Dr. Eleanor Faul, Consultant Colorectal Surgeon at the Mater Misericordiae University Hospital said: “Today’s event is much needed to raise awareness of incontinence and the range of innovative therapies that are available for Irish patients. Technological advancements are enabling the development of new treatment options for those suffering with a loss of bowel control. Moreover, the clinical benefits of surgical technology are clear; they often relieve symptoms when other treatments fail and give a new lease of life to silent sufferers across Ireland.” 

Jackie Fielding, Vice President UK and Ireland at Medtronic, said: “MedTech Week 2017 is an important opportunity for Medtronic to highlight the value of medical technologies. Ireland has a leading role in the vibrant European MedTech industry and there is a need to draw greater awareness to the innovative surgical treatments available. We hope that by partnering with patient groups and clinicians in Ireland in the area of incontinence our MedTech Week event will help bring greater attention to the options available to those affected by incontinence to ensure they no longer suffer in silence.”


IMSTA’s Annual Conference 2017 highlighted  the ‘VALUE of medtech’ in achieving quality patient outcomes.     Defining ‘value’ in health care is currently trending world-wide, not only from an industry perspective – pharma, medtech and ICT,  healthcare providers, clinical communities and academia are all endeavouring to articulate what ‘value’ means to them and how to apply or implement “value-based health care”.  

The following presentations are now available for viewing:

“From Ethics to Innovation, what’s happening in Medtech” Filip Moriau, STRAGLION

“Unlocking the potential of value-based health care ” Dr. Thomas Kelley ICOM

“A Review of Economic Evaluation Frameworks for Medical Technologies” Ms. Rosemary Durcan, Life Sciences & Heathcare Business Consultant

“Achieving Vallue in Healthcare” Mr. Bill Maher, Bons Secours Health System

“Value-based healthcare in practice | Prostate Cancer Outcomes for Value” Prof. Frank Sullivan, NUIG.

“Leveraging Technology to Optimise Healthcare Delivery” Meabh Smith, Beaumont Hospital

“Optimising the Value of medical equipment through implementing holistic equipment management” Mr. Fran Hegarty, Children’s Hospital Group